Mojtaba Shabani-Borujeni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mojtaba Shabani-Borujeni has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Esmaeil Mohammadian
Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran
2 shared publications - Iman Karimzadeh
Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
2 shared publications - Mahmoud Omidi
Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2 shared publications - Manouchehr Jandaghi
Laboratorio de Biología Molecular, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico
2 shared publications - Nikoo Ghasabeh Siahkal-Mahaleh
Student Research Committee, School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University Tehran Medical Sciences
2 shared publications - Seyyed Mobin Rahimnia
Department of pharmaceutics, faculty of pharmacy, Mazandaran university of medical sciences
2 shared publications
Latest Publications
- 28 January 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 37 (16) , 3047-3065
Green and biocompatible formulation of arbutin encapsulated alginate nanoparticle: improved cytotoxicity against melanoma cancer and potent inhibition of melanin biosynthesis and L-DOPA auto-oxidation
The elevated melanin production within the skin results in a distressing pigmentation disorder called melanoma. This underscores the importance of developing effective therapeutic approaches, such as nano-delivery systems. The primary objective of this research was to create alginate (AL) nanoparticle (NP) in gel dosage for improving targeting of arbutin (ARB) as a lightening substance to cure and manage melanoma cancer. Ionic gelation and ultrasonication method were employed to prepare ARB-AL-NP followed by In-vitro assessment of the NP. Outcomes noticed that the optimum ARB-AL-NP were in the size of 252.333 ± 11.873 nm with zeta potential -14.766 ± 0.862, greater encapsulation 89.831 ± 1.081%, and exhibited sustained release of ARB over 6 h (56%). In vitro MTT analysis confirmed that the optimum formulation had higher cell survival on the HFF cell line than kojic-acid and ARB, however, it showed a greater cytotoxic effect on the B16f10 cell line than other groups. Besides, ARB-AL-NP was established to obstruct melanogenesis to a superior level than kojic-acid and ARB and considerably suppress L-dopa auto-oxidation contrasted to kojic-acid and ARB). The outcomes of this assessment confirmed that the ARB-AL-NP could potentially serve as a prospective nanocarrier for ARB cutaneous application, thus unveiling novel approaches for addressing melanoma complaints.
- 28 January 2026
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 37 (16) , 3047-3065
Green and biocompatible formulation of arbutin encapsulated alginate nanoparticle: improved cytotoxicity against melanoma cancer and potent inhibition of melanin biosynthesis and L-DOPA auto-oxidation
The elevated melanin production within the skin results in a distressing pigmentation disorder called melanoma. This underscores the importance of developing effective therapeutic approaches, such as nano-delivery systems. The primary objective of this research was to create alginate (AL) nanoparticle (NP) in gel dosage for improving targeting of arbutin (ARB) as a lightening substance to cure and manage melanoma cancer. Ionic gelation and ultrasonication method were employed to prepare ARB-AL-NP followed by In-vitro assessment of the NP. Outcomes noticed that the optimum ARB-AL-NP were in the size of 252.333 ± 11.873 nm with zeta potential -14.766 ± 0.862, greater encapsulation 89.831 ± 1.081%, and exhibited sustained release of ARB over 6 h (56%). In vitro MTT analysis confirmed that the optimum formulation had higher cell survival on the HFF cell line than kojic-acid and ARB, however, it showed a greater cytotoxic effect on the B16f10 cell line than other groups. Besides, ARB-AL-NP was established to obstruct melanogenesis to a superior level than kojic-acid and ARB and considerably suppress L-dopa auto-oxidation contrasted to kojic-acid and ARB). The outcomes of this assessment confirmed that the ARB-AL-NP could potentially serve as a prospective nanocarrier for ARB cutaneous application, thus unveiling novel approaches for addressing melanoma complaints.
- Open Access
- 6 October 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 14 (2) , e37314
The frequency, risk factors, onset time, and outcome of acute kidney injury induced by vancomycin, colistin, and liposomal amphotericin B in hospitalized patients
Introduction: Medications are among the major causes of acute kidney injury (AKI) in hospitalized patients. Objectives: This study aimed to explore the frequency, characteristics, risk factors, and clinical outcomes of AKI induced by vancomycin, colistin, and liposomal amphotericin B (L-AmB) in hospitalized patients across various wards of two educational hospitals in Shiraz, Iran. Patients and Methods: From October 2022 to May 2023, an observational cross-sectional study was conducted in both intensive care unit (ICU) and non-ICU wards of Namazi and Shahid Faghihi hospitals, Shiraz, Iran. Patients aged 18 and older, without a documented history of AKI or chronic kidney disease, scheduled to receive treatment with vancomycin, colistin, or L-AmB for at least one week, were considered eligible. Relevant data, including demographic, clinical, and laboratory findings, were collected. Results: AKI was observed in 36 (34.3%) out of 105 patients during treatment. The incidence rates of AKI were 29%, 55%, and 31.1% in vancomycin, colistin, and L-AmB recipients, respectively. The mean ± SD time to AKI onset was 5.44 ± 2.04 days (range; 3 to 13 days). Dehydration at admission significantly increased the risk of antibiotic-induced AKI (odds ratio [OR] = 3.686, 95% confidence interval [CI] = 1.226–11.081, P = 0.020). Co-administration of aminoglycosides (OR = 8.422, 95% CI = 1.846 – 38.426, P = 0.006), diuretics (OR = 3.763, 95% CI = 1.092–12.965, P = 0.036), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (OR = 7.149, 95% CI = 1.534–33.308, P = 0.012) were also identified as independent risk factors. The in-hospital mortality rate was significantly higher in patients with AKI than in those without AKI (8.6% vs. 6.7%; P < 0.044). Conclusion: AKI induced by vancomycin, colistin, and L-AmB occurred in about one-third of our study population, primarily within five days of initiating treatment. Dehydration and co-administration of nephrotoxic medications were significantly associated with AKI. Clinicians should explicitly address these factors in preventive strategies to reduce antibiotic-induced AKI in hospitalized patients.
- 6 October 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 14 (2) , e37314
Open AccessThe frequency, risk factors, onset time, and outcome of acute kidney injury induced by vancomycin, colistin, and liposomal amphotericin B in hospitalized patients
Introduction: Medications are among the major causes of acute kidney injury (AKI) in hospitalized patients. Objectives: This study aimed to explore the frequency, characteristics, risk factors, and clinical outcomes of AKI induced by vancomycin, colistin, and liposomal amphotericin B (L-AmB) in hospitalized patients across various wards of two educational hospitals in Shiraz, Iran. Patients and Methods: From October 2022 to May 2023, an observational cross-sectional study was conducted in both intensive care unit (ICU) and non-ICU wards of Namazi and Shahid Faghihi hospitals, Shiraz, Iran. Patients aged 18 and older, without a documented history of AKI or chronic kidney disease, scheduled to receive treatment with vancomycin, colistin, or L-AmB for at least one week, were considered eligible. Relevant data, including demographic, clinical, and laboratory findings, were collected. Results: AKI was observed in 36 (34.3%) out of 105 patients during treatment. The incidence rates of AKI were 29%, 55%, and 31.1% in vancomycin, colistin, and L-AmB recipients, respectively. The mean ± SD time to AKI onset was 5.44 ± 2.04 days (range; 3 to 13 days). Dehydration at admission significantly increased the risk of antibiotic-induced AKI (odds ratio [OR] = 3.686, 95% confidence interval [CI] = 1.226–11.081, P = 0.020). Co-administration of aminoglycosides (OR = 8.422, 95% CI = 1.846 – 38.426, P = 0.006), diuretics (OR = 3.763, 95% CI = 1.092–12.965, P = 0.036), and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (OR = 7.149, 95% CI = 1.534–33.308, P = 0.012) were also identified as independent risk factors. The in-hospital mortality rate was significantly higher in patients with AKI than in those without AKI (8.6% vs. 6.7%; P < 0.044). Conclusion: AKI induced by vancomycin, colistin, and L-AmB occurred in about one-third of our study population, primarily within five days of initiating treatment. Dehydration and co-administration of nephrotoxic medications were significantly associated with AKI. Clinicians should explicitly address these factors in preventive strategies to reduce antibiotic-induced AKI in hospitalized patients.
- Open Access
- 7 November 2023
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2023, 1-8
Drug Utilization Evaluation of Erythropoietin at a Referral Teaching Hospital in Iran
Objectives. Drug utilization evaluation (DUE) studies aim to survey the appropriateness of drug use. DUE is an executive approach used to improve the use of medications as well as reduce the cost of treatment, ensure drug adequacy, and improve patient safety. The aim of this study was to evaluate the pattern of erythropoietin use, according to standard guidelines, in patients admitted to Namazi Hospital in Shiraz, Iran. Methods. In this descriptive, retrospective study, 230 patients were assessed. All patients who were hospitalized in different wards of Namazi Hospital, affiliated to Shiraz University of Medical Sciences, and received at least three doses of erythropoietin from September 2019 to March 2020 participated in this study. The following standard indicators of erythropoietin use were evaluated through reviewing medical charts of the cohort: drug dose, dosing intervals, route of administration, indication, monitoring of laboratory parameters, drug dose adjustment based on the response rate as well as target hemoglobin 12g/dl, attention to major drug interactions, and administration of injectable or oral iron supplementation during treatment. Results. Most (65.2) of the participants were male. The meanSD age of the patients was 47.5522.71years. More than half (51.3) of the included subjects were hospitalized in the nephrology ward. PDpoetin and Cinnapoietin were given to 52.6 and 47.4 of the study participants, respectively. Treatment of anemia due to chronic kidney disease was the most frequent indication of erythropoietin. The time interval of erythropoietin administration was three times a week for 68.3 of the patients. The most frequently administered weekly dose of erythropoietin was 12,000 units. The weekly dose, dose interval, and route of administration of erythropoietin were appropriate in 52.6, 77.4, and 100 of the patients, respectively. Dose adjustment based on the response rate, attention to major drug interactions as well as absolute-relative contraindications, and attention to the target hemoglobin 12 g/dl to decide whether or not to continue treatment were based on standard guideline in 98.1, 98.7, and 93 of the patients, respectively. The sum indexes of erythropoietin use were in line with standard guidelines in 75.84 of the cases. Conclusion. According to our results, in the setting of erythropoietin use in hospitals, physicians need more attention and education in areas such as selecting the proper dose of medication, correct indication of the drug, temporal arrangement of monitoring laboratory items, and the patients need for iron supplements.
- 7 November 2023
- Published by Wiley in Advances in Pharmacological and Pharmaceutical Sciences
- Vol. 2023, 1-8
Open AccessDrug Utilization Evaluation of Erythropoietin at a Referral Teaching Hospital in Iran
Objectives. Drug utilization evaluation (DUE) studies aim to survey the appropriateness of drug use. DUE is an executive approach used to improve the use of medications as well as reduce the cost of treatment, ensure drug adequacy, and improve patient safety. The aim of this study was to evaluate the pattern of erythropoietin use, according to standard guidelines, in patients admitted to Namazi Hospital in Shiraz, Iran. Methods. In this descriptive, retrospective study, 230 patients were assessed. All patients who were hospitalized in different wards of Namazi Hospital, affiliated to Shiraz University of Medical Sciences, and received at least three doses of erythropoietin from September 2019 to March 2020 participated in this study. The following standard indicators of erythropoietin use were evaluated through reviewing medical charts of the cohort: drug dose, dosing intervals, route of administration, indication, monitoring of laboratory parameters, drug dose adjustment based on the response rate as well as target hemoglobin 12g/dl, attention to major drug interactions, and administration of injectable or oral iron supplementation during treatment. Results. Most (65.2) of the participants were male. The meanSD age of the patients was 47.5522.71years. More than half (51.3) of the included subjects were hospitalized in the nephrology ward. PDpoetin and Cinnapoietin were given to 52.6 and 47.4 of the study participants, respectively. Treatment of anemia due to chronic kidney disease was the most frequent indication of erythropoietin. The time interval of erythropoietin administration was three times a week for 68.3 of the patients. The most frequently administered weekly dose of erythropoietin was 12,000 units. The weekly dose, dose interval, and route of administration of erythropoietin were appropriate in 52.6, 77.4, and 100 of the patients, respectively. Dose adjustment based on the response rate, attention to major drug interactions as well as absolute-relative contraindications, and attention to the target hemoglobin 12 g/dl to decide whether or not to continue treatment were based on standard guideline in 98.1, 98.7, and 93 of the patients, respectively. The sum indexes of erythropoietin use were in line with standard guidelines in 75.84 of the cases. Conclusion. According to our results, in the setting of erythropoietin use in hospitals, physicians need more attention and education in areas such as selecting the proper dose of medication, correct indication of the drug, temporal arrangement of monitoring laboratory items, and the patients need for iron supplements.